Si Yi Zhang

Si Yi Zhang

Auto-generated profile, based on publicly available information

Si Yi Zhang

Comprehensive Cancer Centre, King’s College London, London, United Kingdom

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2023 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
CMCarl A. Mitchell
Carl A. Mitchell
EVEvgenia V. Verovskaya
Evgenia V. Verovskaya
FCFernando J. Calero-Nieto
Fernando J. Calero-Nieto
OOOakley C. Olson
Oakley C. Olson
JSJames W. Swann
James W. Swann
EPEmmanuelle Passegué
Emmanuelle Passegué

25 May 2021 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
THTheodore T. Ho
Theodore T. Ho
PDPaul V. Dellorusso
Paul V. Dellorusso
EVEvgenia V. Verovskaya
Evgenia V. Verovskaya
SBSietske T. Bakker
Sietske T. Bakker
JFJohanna Flach
Johanna Flach
EPEmmanuelle Passegué
Emmanuelle Passegué
While young blood can restore many aged tissues, its effects on the aged blood system itself and old hematopoietic stem cells (HSCs) have not been determined. Here, we used transplantation, parabiosis, plasma transfer, exercise, calorie restriction, and aging mutant mice to understand the effects of age-regulated systemic factors on HSCs and their bone marrow (BM) niche. We found that neither exposure to young blood, nor long-term residence in young niches after parabiont separation, nor direct heterochronic transplantation had any observable rejuvenating effects on old HSCs. Likewise, exercise and calorie restriction did not improve old HSC function, nor old BM niches. Conversely, young HSCs were not affected by systemic pro-aging conditions, and HSC function was not impacted by mutations influencing organismal aging in established long-lived or progeroid genetic models. Therefore, the blood system that carries factors with either rejuvenating or pro-aging properties for many other tissues is itself refractory to those factors.

26 April 2023 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
YKYoon-A Kang
Yoon-A Kang
Hyojung PaikHyojung Paik
Hyojung Paik
SZSi Yi Zhang
Si Yi Zhang
JCJonathan J. Chen
Jonathan J. Chen
OOOakley C. Olson
Oakley C. Olson
EPEmmanuelle Passegué
Emmanuelle Passegué
Hematopoietic stem cells (HSC) and downstream lineage-biased multipotent progenitors (MPP) tailor blood production and control myelopoiesis on demand. Recent lineage tracing analyses revealed MPPs to be major functional contributors to steady-state hematopoiesis. However, we still lack a precise resolution of myeloid differentiation trajectories and cellular heterogeneity in the MPP compartment. Here, we found that myeloid-biased MPP3 are functionally and molecularly heterogeneous, with a distinct subset of myeloid-primed secretory cells with high endoplasmic reticulum (ER) volume and FcγR expression. We show that FcγR+/ERhigh MPP3 are a transitional population serving as a reservoir for rapid production of granulocyte/macrophage progenitors (GMP), which directly amplify myelopoiesis through inflammation-triggered secretion of cytokines in the local bone marrow (BM) microenvironment. Our results identify a novel regulatory function for a secretory MPP3 subset that controls myeloid differentiation through lineage-priming and cytokine production and acts as a self-reinforcing amplification compartment in inflammatory stress and disease conditions.

11 September 2025 in Blood
Verified
Journal Article
Open access
BZBernd B. Zeisig
Bernd B. Zeisig
CTChiou-Tsun Tsai
Chiou-Tsun Tsai
CVClemence Virely
Clemence Virely
TFTsz Kan Fung
Tsz Kan Fung
AAAli Tuğrul Akin
Ali Tuğrul Akin
CSChi Wai Eric So
Chi Wai Eric So
Loss-of-function (LoF) mutations frequently found in human cancers are generally intractable by classical small molecule inhibitor approaches. Among them are mutations affecting Polycomb-group (PcG) epigenetic regulators, enhancer of zeste homolog 2 (EZH2) and Additional sex combs like 1 (ASXL1), frequently found in hematological malignancies of myeloid or lymphoid lineage, and their concurrent mutations associates with particularly poor prognosis. Although there is a clear need to develop novel and effective treatments for these patients, the lack of appropriate disease models and mechanistic insights have significantly hindered the progress. Here, we show that genetic inactivation of Asxl1 and Ezh2 in murine hematopoietic stem/progenitor cells results in highly penetrant hematological malignancies as observed in corresponding human diseases. These PcG proteins regulate both coding and noncoding genomes, leading to marked reactivation of transposable elements (TEs) and DNA damage responses in PcG LoF–mutated cells, which create a novel vulnerability for poly(ADP-ribose) polymerase (PARP) inhibitor (PARPi)–induced synthetic lethality. Using both mouse models and primary patient samples, we demonstrate that Asxl1/Ezh2-mutated cells are highly sensitive to PARPis that induce excessive DNA damage and significantly extend disease latency. Intriguingly, the observed PARPi sensitivity can be specifically overridden by reverse transcriptase inhibitors that interrupt target site–primed reverse transcription and life cycle of TEs. This mechanism is contrastingly different from the current concept of BRCAness associated PARPi-induced synthetic lethality, which largely rely on deficient homologous recombination, and is independent on reverse transcriptase inhibitors. Together, this study reveals a novel application and mechanism of PARPi-induced synthetic lethal targeting of blood cancers with reactivated TEs such as those carrying PcG epigenetic mutations.

12 November 2021 in Research Square
Verified
Preprint
Open access
PDF file
CMCarl Mitchell
Carl Mitchell
EVEvgenia Verovskaya
Evgenia Verovskaya
FCFernando Calero-Nieto
Fernando Calero-Nieto
OOOakley Olson
Oakley Olson
XWXiaonan Wang
Xiaonan Wang
EPEmmanuelle Passegué
Emmanuelle Passegué
Hematopoietic aging is marked by a loss of regenerative capacity and skewed differentiation from hematopoietic stem cells (HSC) leading to impaired blood production. Signals from the bone marrow (BM) niche tailor blood production, but the contribution of the old niche to hematopoietic aging remains unclear. Here, we characterize the inflammatory milieu that drives both niche and hematopoietic remodeling. We find decreased numbers and functionality of osteoprogenitors (OPr) and expansion of pro-inflammatory perisinusoidal mesenchymal stromal cells (MSC) with deterioration of the sinusoidal vasculature, which together create a degraded and inflamed old BM niche. Niche inflammation, in turn, drives chronic activation of emergency myelopoiesis pathways in old HSCs and multipotent progenitors (MPP), which promotes myeloid differentiation at the expense of lymphoid and erythroid commitment and hinders hematopoietic regeneration. Remarkably, niche deterioration, HSC dysfunction and defective hematopoietic regeneration can all be ameliorated by blocking IL-1 signaling. Our results demonstrate that targeting IL-1 as a key mediator of niche inflammation is a tractable strategy to improve blood production during aging.